These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2479780)
1. Induction of metachromasia in experimentally induced hyperplastic/hypertrophic changes in the prostate of the cynomolgus monkey (Macaca fascicularis). Habenicht UF; el Etreby MF; Lewis R; Ghoniem G; Roberts J J Urol; 1989 Dec; 142(6):1624-6. PubMed ID: 2479780 [TBL] [Abstract][Full Text] [Related]
2. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione. Habenicht UF; Schwarz K; Neumann F; el Etreby MF Prostate; 1987; 11(4):313-26. PubMed ID: 2446299 [TBL] [Abstract][Full Text] [Related]
3. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies. Habenicht UF; el Etreby MF J Androl; 1991; 12(6):395-402. PubMed ID: 1722796 [TBL] [Abstract][Full Text] [Related]
4. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results. Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF Prostate; 1986; 8(2):181-94. PubMed ID: 2419882 [TBL] [Abstract][Full Text] [Related]
5. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs. Habenicht UF; el Etreby MF Prostate; 1987; 11(2):133-43. PubMed ID: 2444953 [TBL] [Abstract][Full Text] [Related]
6. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review. el Etreby MF J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD). Habenicht UF; el Etreby MF Prostate; 1989; 14(4):309-22. PubMed ID: 2473459 [TBL] [Abstract][Full Text] [Related]
8. Effects of long-term administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostatic hyperplasia. Jeyaraj DA; Udayakumar TS; Rajalakshmi M; Pal PC; Sharma RS J Androl; 2000; 21(6):833-41. PubMed ID: 11105909 [TBL] [Abstract][Full Text] [Related]
9. The function and the role of aromatase inhibitors in the treatment of BPH. el Etreby MF; Habenicht UF Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389 [No Abstract] [Full Text] [Related]
10. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837 [TBL] [Abstract][Full Text] [Related]
11. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K; Ito K; Tamura Y; Suzuki T; Honma S; Yamanaka H Prostate; 1996 May; 28(5):328-37. PubMed ID: 8610061 [TBL] [Abstract][Full Text] [Related]
12. Effect of aromatase inhibitors on the functional morphology of the pituitary gland of dogs and monkeys. Habenicht UF; el Etreby MF Pathol Res Pract; 1988 Sep; 183(5):651-3. PubMed ID: 3237553 [TBL] [Abstract][Full Text] [Related]
13. The periurethral zone of the prostate of the cynomolgus monkey is the most sensitive prostate part for an estrogenic stimulus. Habenicht UF; el Etreby MF Prostate; 1988; 13(4):305-16. PubMed ID: 2464165 [TBL] [Abstract][Full Text] [Related]
14. Effects of estrogen deprivation on human benign prostatic hyperplasia. Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839 [TBL] [Abstract][Full Text] [Related]
15. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. el Etreby MF; Nishino Y; Habenicht UF; Henderson D J Androl; 1991; 12(6):403-14. PubMed ID: 1722797 [TBL] [Abstract][Full Text] [Related]
16. Prostatic basal cell hyperplasia in a cynomolgus monkey (Macaca fascicularis). Wakui S; Furusato M; Kato H; Nomura Y; Kano Y; Aizawa S Vet Pathol; 1989 Sep; 26(5):447-8. PubMed ID: 2480022 [No Abstract] [Full Text] [Related]
17. Metachromasia in the human prostate: a histochemical difference between benign prostatic hyperplasia and prostatic carcinoma. Arcadi JA J Urol; 1988 Feb; 139(2):315-7. PubMed ID: 2448498 [TBL] [Abstract][Full Text] [Related]
18. Stromal cells of the human prostate: initial isolation and characterization. Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397 [TBL] [Abstract][Full Text] [Related]
19. Lovastatin-induced apoptosis in prostate stromal cells. Padayatty SJ; Marcelli M; Shao TC; Cunningham GR J Clin Endocrinol Metab; 1997 May; 82(5):1434-9. PubMed ID: 9141529 [TBL] [Abstract][Full Text] [Related]
20. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. Ho CK; Nanda J; Chapman KE; Habib FK J Endocrinol; 2008 Jun; 197(3):483-91. PubMed ID: 18492814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]